^
    over1year
    A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=248, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    HS-10386